New Targets, New Molecules, New Companies

A New Pharma Ecosystem

This virtual conference aims at connecting topics and scientists across the pharma, biotech, venture capital, and CRO industries discussing the recent promises and challenges of the new pharma ecosystem.

Hosted by Dr. Franz von Nussbaum, Dr. Joerg Fanghaenel and Dr. Uyen Nguyen from NUVISAN, this recording of our virtual conference covers:

  • The development and success of therapeutics beyond “classical” small molecules
  • Novel technologies to address the formerly undruggable and underexplored target space
  • Insight views into the creation of biotech, venture capital, and CRO businesses to meet these new challenges
profile

Introduction

Dr. Franz von Nussbaum

EVP, Head of Life Science Chemistry at NUVISAN

Day 1 - September 29, 2021

Watch Replay
profile

Inducing phase transition in viral condensates. A novel approach to develop antivirals

Dr. Ralf Altmeyer

CEO at Medusa Therapeutics

Day 1 - September 29, 2021

Watch Replay
profile

New science, new technologies… new companies?

Dr. Zachary Sweeney

CEO at Interline Therapeutics

Day 1 - September 29, 2021

No content available

profile

Developing therapeutics by screening large combinatorial libraries of cyclic peptides

Dr. Christian Heinis

Associate Professor at EPFL (École Polytechnique Fédérale de Lausanne)

Day 1 - September 29, 2021

Download Slides
Watch Replay
profile

Controlling the Fate and Function of Proteins with Proximity Photopharmacology

Dr. Dirk Trauner

Professor of Chemistry and Neuroscience & Janice Cutler Chair in Chemistry at New York University

Day 1 - September 29, 2021

Download Slides
Watch Replay
profile

Design and Preclinical Characterization Program Towards BAY 2433334, an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders

Dr. Alexander Hillisch

VP, Head of Computational Molecular Design at Bayer AG

Day 1 - September 29, 2021

No content available

profile

Conclusion

Dr. Franz von Nussbaum

EVP, Head of Life Science Chemistry at NUVISAN

Day 1 - September 29, 2021

Watch Replay
profile

Introduction

Dr. Uyen Nguyen

Head of Scientific Marketing at NUVISAN

Day 2 - September 30, 2021

Watch Replay
profile

Next generation bioconjugates for extra- and intracellular targeting

Dr. Christian Hackenberger

Co-Founder at Tubulis GmbH

Day 2 - September 30, 2021

No content available

profile

Indirect-acting small-molecule inhibitors of Elastase (LasB) for the treatment of P. aeruginosa lung infections

Dr. Anna Hirsch

Head of Drug Design and Optimization department at Helmholtz Institute for Pharmaceutical Research Saarland (HIPS)

Day 2 - September 30, 2021

Download Slides
Watch Replay
profile

Discovery of AhR Antagonist BAY 2416964 for shaping the SMOL IO landscape

Dr. Norbert Schmees

Director of Life Science Chemistry at NUVISAN

Day 2 - September 30, 2021

No content available

profile

Ladder Therapeutics: targeting RNA structure with novel therapies

Dr. Rabia Khan

Founder & CEO at Serna Bio

Day 2 - September 30, 2021

No content available

profile

VC Funding in Biotech

Dr. Dmitrij Hristodorov

Venture Capital Life Science Investor at FORBION

Day 2 - September 30, 2021

Download Slides
Watch Replay
profile

Conclusion

Dr. Joerg Fanghaenel

EVP, Head Lead Discovery at NUVISAN

Day 2 - September 30, 2021

Watch Replay